Key statistics
As of last trade, Lantheus Holdings Inc (0L8:STU) traded at 58.24, 37.81% above the 52 week low of 42.26 set on Sep 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 57.32 |
|---|---|
| High | 58.74 |
| Low | 57.28 |
| Bid | 58.34 |
| Offer | 58.50 |
| Previous close | 57.80 |
| Average volume | 422.00 |
|---|---|
| Shares outstanding | 66.31m |
| Free float | 64.77m |
| P/E (TTM) | 29.14 |
| Market cap | 4.60bn USD |
| EPS (TTM) | 2.38 USD |
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
- Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
- Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
- Lantheus to Present Florbetaben F 18 Data at CTAD 2025
- Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
- Lantheus Announces Leadership Transition Plan
- Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
- Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
- Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
- Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
- Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
More ▼
